David Singer
Managing Partner @ Maverick Ventures
San Francisco, United States
David Singer is a Series A investor at Maverick Ventures in San Francisco focused on Health Care and Biotechnology. Before joining Maverick in 2004, David was the founding CEO of three startups which all became public companies: Affymetrix (NASDAQ: AFFX), Corcept Therapeutics (NASDAQ: CORT) and Genesoft Pharmaceuticals (NASDAQ: OSCI). As an investor for the past 20+ years, David has served on the boards of 28 private companies including seven that went publicduring his service. He is Vice Chair of College Track and is a Lecturer at the Stanford Graduate School of Business. In 2023, 2024 and 2025, David was included in Forbes’ Midas List of the world’s best venture capital investors. David holds an M.B.A. from Stanford and a B.A. from Yale University.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries David Singer invests in
Stages David Singer invests in
Countries David Singer invests in
Investment Focus
Industry
- Health Care 6 (30%)
- Biotechnology 5 (25%)
- Life Science 2 (10%)
- Health Diagnostics 2 (10%)
- Medical 1 (5%)
Stage
- Series A 4 (20%)
- Series C 4 (20%)
- Series B 3 (15%)
- Series D 2 (10%)
- Seed 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Spear Bio
|
Spear Bio is a biotech company that focuses on the detection of ultrasensitive protein. The company was founded in 2021 and is based in Weston, Massachusetts, United States. | $45M / Series A / Jul 29, 2024 | |
Oula Health
|
Oula is redesigning maternity care from the ground up. Its modern maternity center combines the best of obstetrics and midwifery care to deliver a more evidence-based and personalized pregnancy experience. From its collaborative medical team, welcoming clinic, and remote care platform, we are setting a new standard for pregnancy that unifies modernmedicine and human intuition.The company was founded in 2019 and is headquartered in Brooklyn, New York. | $28M / Series B / Feb 20, 2024 | |
|
Spear Bio
|
Spear Bio is a biotech company that focuses on the detection of ultrasensitive protein. The company was founded in 2021 and is based in Weston, Massachusetts, United States. | Seed / Nov 13, 2023 | |
Volta Labs
|
Volta Labs is a biotechnology company that develops scalable automation for genetic engineering. | $20M / Series A / Mar 08, 2022 | |
Collective Health
|
Collective Health gives companies a smarter alternative to traditional health insurance. Through a cloud-based, integrated health benefits platform, the company enables self-insured employers to get more out of their healthcare investment while taking better care of their people. Collective Health has seen exponential traction in the $1.2trillion employer-sponsored insurance market -- its membership has grown by 500x in just three sales cycles. Currently, the company covers 70,000 employees and dependent lives across 15 employers; clients include Activision Blizzard, Crossfit, eBay, Palantir, and Red Bull. | $280M / Series F / May 04, 2021 | |
Seer
|
Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurologicaldiseases, drive earlier treatment and improve patient outcomes. | $55M / Series D / Jul 22, 2020 | |
|
Seer
|
Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurologicaldiseases, drive earlier treatment and improve patient outcomes. | $55M / Series D / Dec 17, 2019 | |
Science Exchange
|
Science Exchange is the world’s leading R&D Services Management company, empowering research organizations to accelerate science and drive more innovation success. The Science Exchange Marketplace improves R&D productivity by automating many collaborative tasks between buyers and providers, such as obtaining quotes, managing projects andprocessing payments, all with rigorous data security and regulatory compliance embedded throughout. | Debt Financing / Oct 16, 2019 | |
|
Science Exchange
|
Science Exchange is the world’s leading R&D Services Management company, empowering research organizations to accelerate science and drive more innovation success. The Science Exchange Marketplace improves R&D productivity by automating many collaborative tasks between buyers and providers, such as obtaining quotes, managing projects andprocessing payments, all with rigorous data security and regulatory compliance embedded throughout. | $20M / Oct 16, 2019 | |
|
Seer
|
Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurologicaldiseases, drive earlier treatment and improve patient outcomes. | $17.5M / Series C / Jul 18, 2019 | |
| See all 20 investments → | |||
Co-Investors
About Maverick Ventures
Maverick Ventures is the venture arm of multi-billion dollar investment firm Maverick Capital. Combining the resources of a global firm with the benefits of an agile, focused team, Maverick Ventures supports entrepreneurs from seed through maturity. With over 30 years of early-stage investment experience, the Maverick Ventures team has funded morethan 100 companies in the healthcare, software and deep technology sectors. The highly-experienced team of operating executives and investors at Maverick Ventures generally lead rounds, take board seats and work with management to build successful enterprises.
Maverick Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Lee Ainslie
Founder
|
|||
Matthew Kinsella
Managing Director
|
|||
Ambar Bhattacharyya
Managing Director
|
|||
|
David Singer
Managing Partner
|
|||
Katherine Gomer
COO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does David Singer invest in?
David Singer invests primarily in Health Care, Biotechnology and Life Science startups, most often at Series A and Series C stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did David Singer last invest?
The most recent investment recorded for David Singer closed in Jul 2024. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
